How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursive’s $400 million outlay represents the bulk of the company’s fundraising to date.

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Researchers have demonstrated for the first time that AI-assisted code can silently rewrite the digital files produced by the forensic DNA machines used in crime labs — the same computerized scan ...

ChatGPT for Teens adds stronger protections for users ages 13 to 17, but parents still face limits around monitoring, age prediction, and AI safety. If you can only read one tech story a day, this is ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...